Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of “Buy” by Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been assigned a consensus recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $54.20.

Several equities research analysts have weighed in on the stock. William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. The Goldman Sachs Group raised their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. Finally, Oppenheimer boosted their target price on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ:TARS opened at $54.41 on Tuesday. The firm’s 50 day simple moving average is $46.51 and its 200 day simple moving average is $35.05. Tarsus Pharmaceuticals has a fifty-two week low of $18.99 and a fifty-two week high of $56.77. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of -14.28 and a beta of 1.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cowen AND Company LLC raised its holdings in Tarsus Pharmaceuticals by 3.5% in the 2nd quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock valued at $59,725,000 after acquiring an additional 74,855 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Tarsus Pharmaceuticals by 47.2% during the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after purchasing an additional 698,712 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Tarsus Pharmaceuticals by 7.3% in the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock worth $37,536,000 after purchasing an additional 77,825 shares during the period. Ikarian Capital LLC grew its stake in Tarsus Pharmaceuticals by 28.7% in the third quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock valued at $33,886,000 after acquiring an additional 230,000 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Tarsus Pharmaceuticals by 8.1% during the third quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock valued at $27,494,000 after buying an additional 62,555 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.